Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group Inc (NQ: REPL )

12.60 +0.16 (+1.29%)
Streaming Delayed Price Updated: 3:40 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group Inc

< Previous 1 2 3 Next >
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace
Replimune Group: Q3 Earnings Insights
Via Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
Via Benzinga
The Latest Analyst Ratings for Replimune Group
Via Benzinga
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session
Via Investor Brand Network
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024
REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
Crude Oil Moves Lower; AutoZone Profit Tops Views
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls 100 Points; ISM Services PMI Increases In November
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Replimune (REPL) Stock Down 48% Today?
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints. 
Via InvestorPlace
US Stocks Down; JM Smucker Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cancer-Focused Replimune Stock Today?
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.